Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAGNASDAQ:CRVONYSE:NNVCNASDAQ:TCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$1.94-0.8%$1.61$1.33▼$3.58$91.39M0.656,883 shs31,187 shsCRVOCervoMed$7.11-8.7%$9.09$1.80▼$22.57$61.88M-0.231.34 million shs162,328 shsNNVCNanoViricides$1.52-3.2%$1.32$0.94▼$3.59$24.43M0.95253,617 shs178,910 shsTCRXTScan Therapeutics$1.44-2.4%$1.38$1.02▼$9.29$81.21M1.06405,784 shs443,333 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene0.00%+6.59%+25.49%-5.37%-30.71%CRVOCervoMed0.00%-16.06%-30.63%+232.24%-62.46%NNVCNanoViricides0.00%-15.08%+16.92%+27.73%-36.67%TCRXTScan Therapeutics0.00%+3.99%-10.31%-22.43%-83.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAGAdagene1.8776 of 5 stars3.33.00.00.02.21.70.0CRVOCervoMed3.5525 of 5 stars4.43.00.00.03.51.70.6NNVCNanoViricidesN/AN/AN/AN/AN/AN/AN/AN/ATCRXTScan Therapeutics3.2317 of 5 stars4.51.00.00.02.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAGAdagene 2.50Moderate Buy$8.00312.37% UpsideCRVOCervoMed 2.89Moderate Buy$27.63288.54% UpsideNNVCNanoViricides 0.00N/AN/AN/ATCRXTScan Therapeutics 3.00Buy$7.80443.55% UpsideCurrent Analyst Ratings BreakdownLatest NNVC, ADAG, CRVO, and TCRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/12/2025CRVOCervoMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $15.005/7/2025TCRXTScan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $10.005/6/2025TCRXTScan TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$7.004/8/2025TCRXTScan TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/3/2025ADAGAdageneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/26/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/18/2025CRVOCervoMedRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $20.003/18/2025CRVOCervoMedCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $21.003/17/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/14/2025TCRXTScan TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$10.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAGAdagene$103.20K885.56N/AN/A$1.61 per share1.20CRVOCervoMed$7.14M8.67N/AN/A$1.30 per share5.47NNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/ATCRXTScan Therapeutics$4.42M18.37N/AN/A$3.15 per share0.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAGAdagene-$18.95MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)CRVOCervoMed-$2.17M-$2.18N/AN/AN/A-118.68%-44.11%-39.81%8/8/2025 (Estimated)NNVCNanoViricides-$8.29M-$0.70N/A∞N/AN/A-87.90%-78.69%N/ATCRXTScan Therapeutics-$89.22M-$1.09N/AN/AN/A-1,188.88%-58.72%-36.02%8/11/2025 (Estimated)Latest NNVC, ADAG, CRVO, and TCRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025CRVOCervoMed-$0.60-$0.56+$0.04-$0.56$1.70 million$1.92 million5/12/2025Q1 2025TCRXTScan Therapeutics-$0.28-$0.26+$0.02-$0.26$1.62 million$2.17 million3/17/2025Q4 2024CRVOCervoMed-$0.67-$0.80-$0.13-$0.80$1.51 million$2.16 million3/5/2025Q4 2024TCRXTScan Therapeutics-$0.27-$0.29-$0.02-$0.30$1.43 million$0.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAGAdageneN/AN/AN/AN/AN/ACRVOCervoMedN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAGAdagene0.082.50N/ACRVOCervoMedN/A15.0415.04NNVCNanoViricidesN/A3.442.47TCRXTScan Therapeutics0.139.569.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAGAdagene9.51%CRVOCervoMed25.15%NNVCNanoViricides10.30%TCRXTScan Therapeutics82.83%Insider OwnershipCompanyInsider OwnershipADAGAdagene21.20%CRVOCervoMed35.40%NNVCNanoViricides4.60%TCRXTScan Therapeutics4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAGAdagene26047.11 million34.89 millionNot OptionableCRVOCervoMed48.70 million3.93 millionNot OptionableNNVCNanoViricides2016.07 million14.92 millionOptionableTCRXTScan Therapeutics10056.59 million51.90 millionNot OptionableNNVC, ADAG, CRVO, and TCRX HeadlinesRecent News About These CompaniesTScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comTScan Therapeutics (NASDAQ:TCRX) & Relay Therapeutics (NASDAQ:RLAY) Head to Head ContrastMay 25, 2025 | americanbankingnews.comLynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) StockMay 22, 2025 | insidertrades.comTScan Therapeutics (NASDAQ:TCRX) Announces Quarterly Earnings ResultsMay 14, 2025 | marketbeat.comEquities Analysts Set Expectations for TCRX Q2 EarningsMay 13, 2025 | marketbeat.comWedbush Equities Analysts Cut Earnings Estimates for TCRXMay 11, 2025 | marketbeat.comResearch Analysts Issue Forecasts for TCRX Q1 EarningsMay 10, 2025 | marketbeat.comWhat Analysts Are Saying About TScan Therapeutics StockMay 10, 2025 | nasdaq.comHC Wainwright Has Lowered Expectations for TScan Therapeutics (NASDAQ:TCRX) Stock PriceMay 9, 2025 | marketbeat.comTScan Therapeutics' (TCRX) "Outperform" Rating Reiterated at WedbushMay 8, 2025 | marketbeat.com3TCRX : What Analysts Are Saying About TScan Therapeutics StockMay 7, 2025 | benzinga.comTScan Therapeutics (TCRX) to Release Earnings on MondayMay 7, 2025 | marketbeat.comTScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comTScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Buy" from AnalystsMay 5, 2025 | marketbeat.comTScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual MeetingApril 30, 2025 | nasdaq.comTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual MeetingApril 28, 2025 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 9.62%April 17, 2025 | aaii.comNeedham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)April 9, 2025 | markets.businessinsider.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 17.27%April 8, 2025 | aaii.comTScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNNVC, ADAG, CRVO, and TCRX Company DescriptionsAdagene NASDAQ:ADAG$1.94 -0.02 (-0.77%) Closing price 05/30/2025 03:59 PM EasternExtended Trading$1.88 -0.06 (-3.35%) As of 05/30/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.CervoMed NASDAQ:CRVO$7.11 -0.68 (-8.73%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$7.20 +0.09 (+1.28%) As of 05/30/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.NanoViricides NYSE:NNVC$1.52 -0.05 (-3.18%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.50 -0.02 (-1.32%) As of 05/30/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.TScan Therapeutics NASDAQ:TCRX$1.44 -0.04 (-2.38%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.43 -0.01 (-0.35%) As of 05/30/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
